Effect of sex and menstrual cycle in women on starting speed, anaerobic endurance and muscle power

The aim of our study was to compare the indicators of starting speed, anaerobic endurance and power in women as well as men, and to investigate whether the values of these indicators differ in women during the follicular and luteal phases of the menstrual cycle. The studied group included 16 men and 16 women. The subjects performed the 20-second maximal cycling sprint test. The men performed the test twice at 14-day intervals. The women undertook the test 4 times: twice during the middle of follicular phase and twice in the middle of luteal phase in separate menstrual cycles. Hormonal changes during the menstrual cycle do not influence anaerobic performance, starting speed or anaerobic endurance in women. Anaerobic performance in men is higher than in women with similar aerobic performance expressed as VO2max/LBM (lean body mass). A lower power decrease with time was noted for women than men, with a similar time of maintaining power in both groups. This is evidence of women’s better anaerobic endurance compared to men. At the same time, the men had significantly better starting speed rates than women

Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade

In case of breast cancer the grade of differentiation and expression of oestrogen and progesterone receptors falls within the first category of prognostic factors according to the College of American Pathologists. HER-2, p53 and Ki67 belong to the second category and their significance still awaits confirmation. The aim of the present study was to examine the relationship between the intensity of expression of oestrogen receptors (ER), progesterone receptors (PgR), HER-2, p53 and Ki67 in cells of ductal breast cancer of G1, G2 or G3 differentiation grade. In paraffin sections of 60 ductal breast cancers (20 cases in G1, 20 in G2 and 20 in G3), immunocytochemical reactions were performed to detect the expression of ER, PgR, HER-2, p53 and Ki67. Following a semi-quantitative appraisal of the preparations under examination, appropriate statistical tests were used to document significant relationships. We noted significant positive correlations between ER and PgR (the entire group studied, G1–3, and the G1 group), HER-2 and p53 (G2) and between p53 and Ki67 expression (G2). Significant negative correlations were found between ER and p53 (G1–3), PgR and p53 (G1–3, G1, G3) and between PgR and Ki67 (G1–3, G2). The studies performed demonstrated distinct relationships between the expression intensity of various proteins in tumour cells in relation to the grade of differentiation of the tumour. We also showed that a parallel determination of ER, PgR and p53 expression may carry high predictive value as to response to tamoxifen treatment

The Role of Bcl-2 and Beclin-1 Complex in “Switching” between Apoptosis and Autophagy in Human Glioma Cells upon LY294002 and Sorafenib Treatment

Background: Gliomas are the most malignant tumors of the central nervous system. One of the factors in their high drug resistance is avoiding programmed death (PCD) induction. This is related to the overexpression of intracellular survival pathways: PI3K-Akt/PKB-mTOR and Ras-Raf-MEK-ERK. Apoptosis and autophagy are co-existing processes due to the interactions between Bcl-2 and beclin-1 proteins. Their complex may be a molecular “toggle-switch” between PCD types. The aim of this research was to investigate the role of Bcl-2:beclin-1 complex in glioma cell elimination through the combined action of LY294002 and sorafenib. Methods: Drug cytotoxicity was estimated with an MTT test. The type of cell death was evaluated using variant microscopy techniques (fluorochrome staining, immunocytochemistry, and transmission electron microscopy), as well as the Bcl-2:beclin-1 complex formation and protein localization. Molecular analysis of PCD indicators was conducted through immunoblotting, immunoprecipitation, and ELISA testing. SiRNA was used to block Bcl-2 and beclin-1 expression. Results: The results showed the inhibitors used in simultaneous application resulted in Bcl-2:beclin-1 complex formation and apoptosis becoming dominant. This was accompanied by changes in the location of the tested proteins. Conclusions: “Switching” between apoptosis and autophagy using PI3K and Raf inhibitors with Bcl-2:beclin-1 complex formation opens new therapeutic perspectives against gliomas

Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients

Background: Estrogen receptor beta (ERβ) belongs to a large family of nuclear receptors. Recent studies have suggested that ERβ in contrast to ERα might act as a tumour suppressor in ovarian cancer (OVCA). Materials and Methods: Expression of ERβ was detected by immunocytochemistry in 11 OVCA cell lines and by immunohistochemistry in 43 (41 FIGO stage III) OVCA specimens prepared before chemotherapy and 30 specimens from the same group after chemotherapy. Cisplatin sensitivity in the 11 cell lines was also analysed. Results: No significant correlations between cisplatin-sensitivity and expression of ERβ was found in the cell lines. In the cases which responded well to chemotherapy (complete response) ERβ expression at preliminary laparotomy (PL) was significantly higher (p=0.0004) than in those with progressive disease. Kaplan-Meier analysis revealed that the patients with higher ERβ expression (>30% of cells) at PL had an increased overall survival time and progression-free time (p=0.00161 and p=0.03255, respectively) than the patients with lower ERβ espression. Significantly shorter overall survival time characterized the cases with lower immunoreactivity score of ERβ expression at secondary cytoreduction (SCR) (p=0.00346). Conclusion: The loss of ERβ expression in ovarian tumours may be a feature of malignant transformation

Facile hydrothermal synthesis of economically viable VO2(M1) counter electrode for dye sensitized solar cells

In this study, we focus at reducing the fabrication cost of dye sensitized solar cells (DSSCs). Sphere-like VO2(M1) polymorph was synthesized by single step facile hydrothermal approach using citric acid as the reducing agent. Phase purity, charge state and surface morphology of the synthesized product was confirmed by X-ray diffraction, X-ray photoelectron spectroscopy and scanning electron microscopy respectively. The electrochemical impedance and cyclic voltammograms of VO2 films indicated a good electrocatalytic activity towards redox reaction of the I−/I3− shuttle. Owing to the low cost, low-temperature processing and good catalytic activity, in this work we propose to use VO2 as a counter electrode to substitute the expensive platinum electrode in DSSCs. By means of VO2 based DSSCs we achieved a fivefold reduction in the cost to energy conversion efficiency ratio. It is expected that with further optimization, VO2 can be exploited as a good candidate for counter electrode in DSSC technology

Literatura Niewidocznego — wizje i rewizje urban fantasy

A discussion Literature of the Unseen—Visions and (Re)visions of Urban Fantasy collects theoretical reflections upon the subgenres of urban fantasy and paranormal romance, along with a brief commentary on the body of text representative for both conventions. Participants include „Creatio Fantastica” editors—Sylwia Borowska-Szerszun, Krzysztof M. Maj, and Barbara Szymczak-Maciejczyk—as well as renowned experts in the field of fantasy studies: Stefan Ekman, author of the first monograph of fantasy map-making, Here Be Dragons. Exploring Fantasy Maps & Settings (2013), and Audrey Taylor, author of Patricia A. McKillip and the Art of Fantasy World-building (2017)

Stromal myofibroblasts in breast cancer: relations between their occurrence, tumor grade and expression of some tumour markers

It is suggested that tumour stromal myofibroblasts exert an unfavourable effect on the biology of breast cancer. We are aware of only a single study which examined relationships between manifestation of myofibroblasts in the stroma of breast cancer and clinicopathological data of the patients. The present study was aimed at estimation of the effect exerted by myofibroblasts present in the tumour stroma on principal pathological parameters and on expression of Ki67, P53 and HER-2 proteins in the group of the most frequent breast cancers, the ductal cancers. In paraffin sections of 60 ductal breast cancers (20 cases in G1, 20 in G2 and 20 in G3), immunohistochemical reactions were performed to detect expression of smooth muscle actin (SMA) in order to visualize myofibroblasts, Ki67, P53 and HER-2. The studies demonstrated that the most numerous myofibroblasts were present in G3 cases and they were the least frequent in G1 cases (P = 0.02). Positive correlations were observed between the presence of myofibroblasts in tumour stroma and expression of Ki67 and HER-2 in breast cancer cells in the entire group (P < 0.001 and P = 0.001, respectively), in G2 cases (P = 0.003 and P = 0.03) and in G3 cases (P = 0.01 and P = 0.03). Considering that the higher grade, Ki67 and HER-2 are thought to represent unfavourable prognostic factors, the elevated content of myofibroblasts in tumour stroma is probably typical for cases with worse prognosis